PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: BioSim Pharmaceuticals, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BioSim Pharmaceuticals is Focused on Building a Portfolio of Generic Drugs for the Orphan Diseases - BioSim Pharmaceuticals issues public request to Oppenheimer & Co. for retraction of Research Note - BioSimLLC.com
BioSim Pharmaceuticals is Focused on Building a Portfolio of Generic Drugs for the Orphan Diseases

 

NewswireToday - /newswire/ - Seattle, WA, United States, 2012/08/08 - BioSim Pharmaceuticals issues public request to Oppenheimer & Co. for retraction of Research Note - BioSimLLC.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This release is a public request being issued to Oppenheimer & Co. to remove or correct a Questcor Corp. investment note dated Monday July 16, 2012 by Oppenheimer associate Christopher Holterhoff. Holterhoff's published note that the BioSimllc.com “website is illegitimate” and in turn, BioSim Pharmaceuticals, is inaccurate.

BioSim Pharmaceuticals, is a pharmaceuticals company focused on making affordable generics for orphan diseases. Holterhoff‘s writing of “We question the validity and legitimacy of this website and the company behind it” can be considered improper due diligence as each and every claim made has been disproven. Just a few of the inaccurate claims are that since BioSim Pharmaceuticals LLC is not registered with the Washington State Secretary of State that BioSim must not be a legitimate corporation. The fact is that BioSim is actually registered in the State of Nevada, and filed there before we became public. This may be verified with the Nevada secretary of state website. The additional claim that our address is invalid is incorrect. The address on the website is our mailing address and registered with the US postal service. Our research is conducted at another location, which is confidential. At no time did any of Oppenheimer representatives email or leave a message with BioSim requesting information in creating this research note.

BioSim is very concerned with the content of this research note. BioSim is actively engaged with the FDA in gaining approval of its first generic, a highly purified ACTH gel, whereas biosimllc.com will be posting evidence of the upcoming meeting along with other information disproving Oppenheimer's research note. We request an immediate retraction of the statements made.

About BioSim Pharmaceuticals

BioSim (biosimllc.com), a Seattle-based pharmaceutical company, focuses on building a portfolio around generic drugs for the orphan disease markets. BioSim consists of a team of highly capable individuals working together to implement both the near, and long-term objectives of advancing our pre-clinical and clinical development, all the way through late-stage development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: BioSim Pharmaceuticals, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BioSim Pharmaceuticals is Focused on Building a Portfolio of Generic Drugs for the Orphan Diseases

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Abe Panitch - BioSimLLC.com 
206-552-0630 press[.]biosimllc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BioSim Pharmaceuticals, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BioSim Pharmaceuticals, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)